Enhancing Care in Abu Dhabi: The New ABA Guidelines for Autism

By HEOR Staff Writer

October 2, 2024

Introduction

The Department of Health – Abu Dhabi (DoH) has recently introduced Applied Behavioural Analysis (ABA) guidelines for Autism Spectrum Disorder (ASD). These guidelines aim to improve care for People of Determination (PoD) and align with Abu Dhabi’s Comprehensive Strategy for PoD 2020-2024. This strategy aims to shift the perception of disabilities from a medical to a societal and rights-based model.

Understanding Applied Behavioural Analysis

ABA is a research-based therapy designed for individuals with autism and other developmental disorders. Its primary goal is to increase positive behaviours and reduce negative ones. The newly launched ABA guidelines in Abu Dhabi focus on enhancing the quality and consistency of ABA services for people with ASD. This initiative is part of a broader effort to standardise ASD care, integrating evidence-based practices with international standards.

The Importance of Standardised Care

One of the main objectives of the new ABA guidelines is to provide a comprehensive framework that empowers healthcare and education professionals. By fostering seamless collaboration, these guidelines aim to deliver holistic and impactful care for individuals with ASD. The emphasis is on children and their families, ensuring that they receive integrative care and improved access to ABA therapy. Dr. Rashed Obaid Al Suwaidi, Executive Director of Healthcare Workforce Planning at DoH, stated, “Abu Dhabi is dedicated to fostering an inclusive environment that ensures equitable access for PoD, empowering them to reach their full potential.” This commitment underlines Abu Dhabi’s position as a leading destination for healthcare.

Cost and Accessibility of ABA Therapy

The cost of autism therapy in Dubai varies, with ABA therapy sessions ranging from 300 to 800 AED per hour. Many insurance plans cover ABA therapy, making it more accessible for families. Some therapy centres also offer flexible payment plans based on a family’s income. Investing in quality therapy can yield long-term benefits, outweighing initial costs.

Effectiveness of ABA Therapy

ABA therapy is widely recognised as an effective treatment for children with autism. Studies indicate that up to 90% of children with autism show significant progress in communication and learning skills with intensive ABA therapy. Around 50% of these children can reach a level of functioning comparable to their neurotypical peers. The success rate of ABA therapy highlights its efficacy, making it a valuable option for families in Abu Dhabi.

Optimal Age for ABA Therapy

Early intervention is crucial for optimal outcomes in ABA therapy. Experts recommend starting therapy as soon as a child receives an autism diagnosis, which can be as early as 18 months old. However, ABA therapy can benefit children of all ages. The structured, evidence-based approach of ABA helps children develop new skills and reduce challenging behaviours, regardless of their age.

Conclusion

The new ABA guidelines for ASD in Abu Dhabi represent a significant step towards improving care for PoD. By standardising ABA services and fostering collaboration between healthcare and education professionals, these guidelines aim to provide holistic and impactful care for individuals with ASD. With a focus on accessibility and effectiveness, ABA therapy offers a promising path for families seeking support for their neurodivergent children.

Reference url

Recent Posts

EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public Health Emergencies

By HEOR Staff Writer

March 9, 2026

The European Medicines Agency (EMA) has released draft clinical trials guidance for public consultation from 4 March to 30 April 2026. This guidance outlines regulatory flexibi...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Compliance and Participant ...
Portugal Aligns with EU Standards Portugal clinical trials regulation is now firmly established through Lei n.º 9/2026, published on March 6, 2026, which implements the European Parliament and Council
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU

By João L. Carapinha

March 4, 2026

EMA's Push for Microbiome Medicinal Products Guidance EMA's Non-Clinical Working Party has drafted a concept paper, adopted by CHMP on 16 February 2026, proposing a reflection paper to guide non-clinical development of microbiome...